Eiger BioPharmaceuticals and Merck will expand their licensing agreement to include Eiger's rights to develop the Hutchinson-Gilford Progeria syndrome treatment lonafarnib. Eiger, in a separate agreement, will provide the Progeria Research Foundation lonafarnib for its ongoing clinical trials as well as expanded access in Progeria and will take responsibility for any potential new drug application filing for Progeria indication resulting from those trials.
Eiger expands deal with Merck, provides lonafarnib to Progeria
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.